Merck, Inc.
MK-5475-013 INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of MK-5475 (an Inhaled sGC Stimulator) in Adults With PH-COPD
- Conditions
- Interventions
- First Posted Date
- 2022-11-10
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 120
- Registration Number
- NCT05612035
- Locations
- 🇺🇸
University of Colorado Anschutz Medical Campus-University of Colorado Hospital Cardiac and Vascular, Aurora, Colorado, United States
🇺🇸Clinovation Intl. Corp. ( Site 0108), Sebring, Florida, United States
🇺🇸Alexian Brothers Medical Center-Pulmonary ( Site 0109), Elk Grove Village, Illinois, United States
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
- Conditions
- Interventions
- First Posted Date
- 2022-11-08
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 614
- Registration Number
- NCT05609968
- Locations
- 🇺🇸
Houston Methodist Hospital ( Site 0419), Houston, Texas, United States
🇷🇴Cardiomed SRL Cluj-Napoca ( Site 0217), Cluj-Napoca, Cluj, Romania
🇺🇸Infirmary Cancer Care ( Site 0418), Mobile, Alabama, United States
Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)
- First Posted Date
- 2022-11-02
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 99
- Registration Number
- NCT05602727
- Locations
- 🇺🇸
Neurology Center of North Orange County ( Site 0039), Fullerton, California, United States
🇨🇦Sunnybrook Health Sciences Centre ( Site 0106), Toronto, Ontario, Canada
🇺🇸Richmond Behavioral Associates ( Site 0008), Staten Island, New York, United States
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study
- Conditions
- Interventions
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 94
- Registration Number
- NCT05600309
- Locations
- 🇨🇳
Hainan General Hospital ( Site 1177), Haikou, Hainan, China
🇨🇳Fujian Province Cancer Hospital ( Site 1178), Fuzhou, Fujian, China
🇨🇳The Sixth Affiliated Hospital of Sun Yat-sen University ( Site 1159), Guangzhou, Guangdong, China
A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001)
- Conditions
- Interventions
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 90
- Registration Number
- NCT05594043
- Locations
- 🇺🇸
Sanford Cancer Center ( Site 0300), Sioux Falls, South Dakota, United States
🇨🇦Princess Margaret Cancer Centre ( Site 0101), Toronto, Ontario, Canada
🇨🇭Hôpitaux Universitaires de Genève (HUG) ( Site 0202), Genève, Geneve, Switzerland
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
- First Posted Date
- 2022-10-20
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 42
- Registration Number
- NCT05587712
- Locations
- 🇺🇸
The Regents of the University of California - Los Angeles (UCLA Pediatrics) ( Site 1606), Los Angeles, California, United States
🇺🇸Stanford University School of Medicine ( Site 1603), Palo Alto, California, United States
🇺🇸UCSF Benioff Children's Hospital San Francisco ( Site 1611), San Francisco, California, United States
Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)
- Conditions
- Interventions
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1484
- Registration Number
- NCT05569954
- Locations
- 🇩🇪
Universitaetsklinikum Hamburg-Eppendorf-Infektiologie ( Site 0901), Hamburg, Germany
🇰🇷Asan Medical Center ( Site 1809), Seoul, Korea, Republic of
🇰🇷Ewha Womans University Mokdong Hospital-Infectious Diseases ( Site 1805), Seoul, Korea, Republic of
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
- Conditions
- Interventions
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 40
- Registration Number
- NCT05562830
- Locations
- 🇨🇱
FALP-UIDO ( Site 1151), Santiago, Region M. De Santiago, Chile
🇮🇱Rambam Health Care Campus-Oncology ( Site 1501), Haifa, Israel
🇺🇸Cleveland Clinic-Taussig Cancer Center ( Site 1036), Cleveland, Ohio, United States
Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017)
- Conditions
- Interventions
- First Posted Date
- 2022-09-29
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 116
- Registration Number
- NCT05559905
- Locations
- 🇬🇧
hVIVO Services ( Site 0001), London, London, City Of, United Kingdom
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)
- Conditions
- Interventions
- First Posted Date
- 2022-09-02
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1080
- Registration Number
- NCT05526716
- Locations
- 🇺🇸
Optimal Research ( Site 0008), Melbourne, Florida, United States
🇺🇸Holston Medical Group-Clinical Research ( Site 0009), Kingsport, Tennessee, United States
🇺🇸Triple O Research Institute, P.A ( Site 0054), West Palm Beach, Florida, United States